As of December 31, 2024, Fortress' consolidated cash and cash equivalents totaled $57.3 million, compared to $58.9 million as ...

Attendees boosted their financial well-being at the 18th annual Money Power Day, the region's largest free financial fitness ...

MT-601, Marker's lead MAR-T cell therapy, is being evaluated in the nationwide multicenter Phase 1 APOLLO study ( clinicaltrials.gov identifier: NCT05798897) in patients with anti-CD19 CAR-T relapsed ...